Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System

References

• World Health Oganization. Overview of diabetes. Available from https://www.who.int/health-topics/diabetes#tab=tab_1. Accessed Mar 31, 2023.
   Google Scholar
• Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020 May 11;8(2):14. doi: 10.3390/diseases8020014
   PubMedGoogle Scholar
• Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Oct;16(10):556–577. doi: 10.1038/s41574-020-0392-2
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S140–S157. doi: 10.2337/dc23-S009
   PubMedGoogle Scholar
• Radholm K, Wu JH, Wong MG, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - a systematic review. Diabet Res Clin Pract. 2018 Jun;140:118–128
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013 Sep 14;382(9896):941–950. doi: 10.1016/S0140-6736(13)60683-2
   PubMed Web of Science ®Google Scholar
• Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol. 2015 Dec 23;14(1):154. doi: 10.1186/s12933-015-0314-0
   PubMedGoogle Scholar
• Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004–1016. doi: 10.1016/S2213-8587(16)30267-4
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Aug 20;159(4):262–274. doi: 10.7326/0003-4819-159-4-201308200-00007
   PubMed Web of Science ®Google Scholar
• Han SJ, Ha KH, Lee N, et al. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study. Diab Obes Metab. 2021 Mar;23(3):682–691. doi: 10.1111/dom.14261
   PubMed Web of Science ®Google Scholar
• Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573
   PubMedGoogle Scholar
• Weiss-Smith S, Deshpande G, Chung S, et al. The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med. 2011 Mar 28;171(6):591–593. doi: 10.1001/archinternmed.2011.89
   PubMedGoogle Scholar
• He Z, Lam K, Zhao W, et al. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetol. 2023 Mar;60(3):401–411. doi: 10.1007/s00592-022-02015-6
   PubMed Web of Science ®Google Scholar
• Shen J, Yang J, Zhao B. A survey of the FDA’s adverse event reporting System database concerning urogenital tract infections and Sodium glucose cotransporter-2 inhibitor use. Diabetes Ther. 2019 Jun;10(3):1043–1050. doi: 10.1007/s13300-019-0611-9
   PubMed Web of Science ®Google Scholar
• Zhou X, Ye X, Guo X, et al. Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS. Front Pharmacol. 2021;12:766125. doi: 10.3389/fphar.2021.766125
   PubMed Web of Science ®Google Scholar
• Bohm R, von Hehn L, Herdegen T, et al. OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016;11(6):e0157753. doi: 10.1371/journal.pone.0157753
   PubMed Web of Science ®Google Scholar
• Zhao Z, Tang Y, Hu Y, et al. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. Ann Transl Med. 2021 Sep;9(18):1482. doi: 10.21037/atm-21-4162
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab347
   PubMed Web of Science ®Google Scholar
• Puckrin R, Saltiel MP, Reynier P, et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018 May;55(5):503–514. doi: 10.1007/s00592-018-1116-0
   PubMed Web of Science ®Google Scholar
• Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019 Feb 1;9(1):e022577. doi: 10.1136/bmjopen-2018-022577
   PubMed Web of Science ®Google Scholar
• Ahmed AE, Abdelkarim S, Zenida M, et al. Prevalence and associated risk factors of urinary tract infection among diabetic patients: a cross-sectional study. Healthcare. 2023 Mar 15;11(6):861. doi: 10.3390/healthcare11060861
   Web of Science ®Google Scholar
• Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005;28(11):981–1007. doi: 10.2165/00002018-200528110-00002
   PubMed Web of Science ®Google Scholar